Latomno

Lurasidone, the active ingredient in Latomno, is an atypical antipsychotic presented as a tablet for oral use. It is indicated for the treatment of schizophrenia and bipolar depression in adult patients. GNH USA supplies Latomno as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lurasidone is an atypical antipsychotic that modulates dopamine and serotonin pathways in psychiatric disorders. - Schizophrenia: reduces positive and negative psychotic symptoms and helps maintain stability. - Bipolar depression: alleviates depressive episodes in bipolar I disorder. - Maintenance of schizophrenia: lowers risk of relapse when used as long‑term therapy.

Lurasidone may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: transient gastrointestinal discomfort. - Akathisia: inner restlessness or inability to stay still. - Somnolence: drowsiness or fatigue. - Headache: mild to moderate intensity. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Seizures: especially in patients with pre‑existing risk. - Orthostatic hypotension: dizziness upon standing. - Suicidal thoughts: emergence of suicidal ideation. - Agranulocytosis: severe drop in white‑blood cell count.

Before initiating therapy, clinicians should evaluate several safety considerations. - Monitor metabolic parameters: regularly check weight, fasting glucose, and lipid profile. - Assess for suicidal ideation: especially during early treatment phases. - Avoid abrupt discontinuation: taper dose under medical supervision to reduce withdrawal risk. - Use caution in cardiovascular disease: monitor blood pressure and ECG for hypotension or arrhythmia. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Lurasidone interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase lurasidone plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may substantially reduce efficacy. - Other QT‑prolonging antipsychotics: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely):\n- Serotonergic agents (e.g., SSRIs, SNRIs): potential for serotonin syndrome. - CNS depressants (e.g., alcohol, benzodiazepines): enhanced sedation and respiratory depression. - Antihypertensive drugs: possible additive hypotensive effect.